VIVE (Viveve Medical) Beginning Cash Position: $9.43 Mil (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VIVE Viveve Medical Inc VIVE
12 GF Score
Price $0.00
View Full Analysis

What is Viveve Medical Beginning Cash Position?

Viveve Medical VIVE 12 Beginning Cash Position is $9.43 Mil as of Sep. 2022. GuruFocus rates VIVE with a GF Score™ of 12/100.

Viveve Medical's Beginning Cash Position for the quarter that ended in Sep. 2022 was $9.43 Mil.

Viveve Medical's quarterly Beginning Cash Position declined from Mar. 2022 ($19.16 Mil) to Jun. 2022 ($14.05 Mil) and declined from Jun. 2022 ($14.05 Mil) to Sep. 2022 ($9.43 Mil).

Viveve Medical's annual Beginning Cash Position declined from Dec. 2019 ($29.52 Mil) to Dec. 2020 ($13.31 Mil) and declined from Dec. 2020 ($13.31 Mil) to Dec. 2021 ($6.52 Mil).

Viveve Medical Beginning Cash Position Related Terms

Viveve Medical Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Viveve Medical's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viveve Medical Beginning Cash Position Chart

Viveve Medical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.09 20.73 29.52 13.31 6.52

Viveve Medical Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.39 22.67 19.16 14.05 9.43
VIVE
12GF Score
Viveve Medical Inc VIVE
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viveve Medical Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $9.43 Mil mean?
Viveve Medical (VIVE) has a Beginning Cash Position of $9.43 Mil as of Sep. 2022. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Viveve Medical and its competitors.
Is Viveve Medical's Beginning Cash Position too high?
Viveve Medical's current Beginning Cash Position is $9.43 Mil. Overall, Viveve Medical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Viveve Medical's Beginning Cash Position compare to NNMX and LHDXQ?
Viveve Medical's Beginning Cash Position of $9.43 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Viveve Medical and its competitors. Viveve Medical's current Beginning Cash Position is $9.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viveve Medical stock overvalued right now?
Viveve Medical (VIVE) has a current Beginning Cash Position of $9.43 Mil. The current Beginning Cash Position is $9.43 Mil. Viveve Medical's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Viveve Medical (VIVE), the current Beginning Cash Position is $9.43 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viveve Medical Business Description

Address 345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112
Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.
12GF Score

Get the complete analysis for VIVE

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price